Compare GEMI & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GEMI | PHAR |
|---|---|---|
| Founded | 2014 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2025 | N/A |
| Metric | GEMI | PHAR |
|---|---|---|
| Price | $7.51 | $15.52 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 2 |
| Target Price | $20.00 | ★ $38.00 |
| AVG Volume (30 Days) | ★ 1.5M | 37.7K |
| Earning Date | 11-14-2025 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.00 |
| Revenue | $162,529,000.00 | ★ $362,274,000.00 |
| Revenue This Year | $20.81 | $25.19 |
| Revenue Next Year | $79.83 | $4.47 |
| P/E Ratio | ★ N/A | $2,833.20 |
| Revenue Growth | ★ 65.61 | 26.78 |
| 52 Week Low | $6.47 | $7.50 |
| 52 Week High | $45.89 | $21.34 |
| Indicator | GEMI | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 34.44 | 36.80 |
| Support Level | $6.47 | $15.26 |
| Resistance Level | $8.05 | $16.48 |
| Average True Range (ATR) | 0.65 | 0.66 |
| MACD | -0.06 | -0.43 |
| Stochastic Oscillator | 17.38 | 4.27 |
Gemini Space Station Inc is engaged on unlocking the next era of financial, creative, and personal freedom. It envisions a future where crypto will redesign the global financial system, the internet, and money in a way that provides greater choice, independence, and opportunity for all. As a trusted bridge between the traditional financial system and the emerging crypto economy, It is providing access for individuals and institutions to a decentralized future that is more open, fair, and secure. Its core exchange product has expanded over time to become a comprehensive platform for its users to engage with the crypto economy, including a derivatives exchange, staking services, an over-the-counter (OTC) trading desk, institutional-grade custody, and others.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.